Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054234 | 0.87 | KMT2A (0.46) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL21550234 | 0.87 | MAPT (0.47) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL538007 | 0.86 | KMT2A (0.65) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL440533 | 0.86 | KMT2A (0.65) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL538577 | 0.85 | KMT2A (0.46) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4152079 | 0.84 | MAPT (0.52) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL9032332 | 0.84 | MAPT (0.45) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL8731869 | 0.83 | MAPT (0.44) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL30892705 | 0.82 | KMT2A (0.42) | MAPTKMT2AMEN1NPC1RAB9A | |
| SCHEMBL29281913 | 0.82 | KMT2A (0.42) | MAPTKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598159-B2 | Therapeutic pyrazoloquinoline derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-12-03 | — | — | US | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2166852-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | MAPT 461/4885KMT2A 2970/4885MEN1 3172/4885 |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | MAPT 461/4885KMT2A 2970/4885MEN1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.